David A.  Vort net worth and biography

David Vort Biography and Net Worth

David A. Vort has served as iRhythm’s Chief Commercial Officer since December 2021. Previously, he was iRhythm’s Executive Vice President of Sales since January 2014. Prior to joining iRhythm, he was Vice President of US Sales at InTouch Health, a provider of telemedicine and remote presence solutions. Prior to that, Mr. Vort served as Area Vice President of Western Sales for Intuitive Surgical, Inc., the manufacturer of the da Vinci Surgical Robotics system. Before that, Mr. Vort was the Revision Business Sales Director for Stryker Corporation. Mr. Vort also founded and held several positions domestically and in Europe for the Global Healthcare Exchange, LLC. In his early career, he held several positions with U.S. Surgical Corporation, prior to its sale to Covidien plc. Mr. Vort holds a B.S. in Political Science from the University of the Pacific.

What is David A. Vort's net worth?

The estimated net worth of David A. Vort is at least $2.45 million as of January 26th, 2021. Mr. Vort owns 27,126 shares of iRhythm Technologies stock worth more than $2,451,919 as of December 22nd. This net worth evaluation does not reflect any other investments that Mr. Vort may own. Learn More about David A. Vort's net worth.

How do I contact David A. Vort?

The corporate mailing address for Mr. Vort and other iRhythm Technologies executives is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. iRhythm Technologies can also be reached via phone at (415) 632-5700 and via email at [email protected]. Learn More on David A. Vort's contact information.

Has David A. Vort been buying or selling shares of iRhythm Technologies?

David A. Vort has not been actively trading shares of iRhythm Technologies within the last three months. Learn More on David A. Vort's trading history.

Who are iRhythm Technologies' active insiders?

iRhythm Technologies' insider roster includes C. Bairey Merz (Director), Quentin Blackford (CEO), Mark Day (EVP), Douglas Devine (CFO), Patrick Murphy (EVP), Chad Patterson (Chief Commercial Officer), Sumi Shrishrimal (EVP, Chief Risk Officer), Mervin Smith (EVP of Business Operations), Minang Turakhia (Chief Medical Officer, Chief Scientific Officer and EVP, Product Innovation), David Vort (EVP), and Daniel Wilson (EVP). Learn More on iRhythm Technologies' active insiders.

Are insiders buying or selling shares of iRhythm Technologies?

In the last year, iRhythm Technologies insiders bought shares 2 times. They purchased a total of 6,944 shares worth more than $521,860.64. In the last year, insiders at the sold shares 13 times. They sold a total of 69,024 shares worth more than $7,151,438.22. The most recent insider tranaction occured on December, 2nd when insider Patrick Michael Murphy sold 2,492 shares worth more than $214,037.88. Insiders at iRhythm Technologies own 0.7% of the company. Learn More about insider trades at iRhythm Technologies.

Information on this page was last updated on 12/2/2024.

David A. Vort Insider Trading History at iRhythm Technologies

See Full Table

David A. Vort Buying and Selling Activity at iRhythm Technologies

This chart shows David A. Vort's buying and selling at iRhythm Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

iRhythm Technologies Company Overview

iRhythm Technologies logo
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $90.39
Low: $85.29
High: $91.22

50 Day Range

MA: $80.38
Low: $57.94
High: $91.45

2 Week Range

Now: $90.39
Low: $55.92
High: $124.11

Volume

506,936 shs

Average Volume

465,130 shs

Market Capitalization

$2.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26